Abattis Bioceuticals (ATTBF) 0.0400 $ATTBF
Cannabis Companies Hunt for Financing, Growth
at The Street - Fri Sep 25, 9:51AM CDT
Companies in the cannabis business have an appetite for capital to fuel what has emerged as one of the largest growth sectors, and more investors are taking the risk.
XXII: 1.08 (unch), FB: 93.24 (+0.77), PYPL: 32.06 (+0.39), ARNA: 2.19 (+0.14)
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 1.08 (unch), INSY: 25.65 (+0.64), ARNA: 2.19 (+0.14)
Abba Medix Builds a Diversified Business
ACCESSWIRE - Wed Jul 08, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 8, 2015 / Health Canada expects the country's medical marijuana market to dramatically expand over the coming years, growing from 22,000 patients in 2012 to more than 450,000 by 2024, representing a nearly 30% compounded annual growth rate. In dollar terms, the federal agency expects the market to reach approximately $1.2 billion in size, as the market moves from primarily home-growing to industrialized growers approved under the MMPR.
OGI.VN: 0.295 (+0.010), TWD.VN: 1.810 (-0.020), VPCO: 0.58 (+0.02)
Nutritional High Poised to Execute on U.S. Edibles Strategy, Hails Canadian Court Ruling
ACCESSWIRE - Tue Jul 07, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 7, 2015 / Currently exclusively focused on manufacturing and distributing marijuana infused products (MIPs) like edibles and oils, as well as extracts produced with reliable semi automated processes, across U.S. states where such activity is already legal, Nutritional High International (OTCQB: SPLIF) (CSE: NHL) is coming out swinging with universally identifiable branding, featuring marijuana icon Jimi Hendrix on precisely formulated products that will survive longer on the shelf, taking the guesswork out of edibles for retailers and consumers alike. The company's strategy to leverage such iconic branding and roll out a number of marijuana and hemp oil-infused edibles in the U.S. and Canada bearing his likeness, was highlighted by David Posner, president and CEO of Nutritional High, in a recent interview with CannabisFN's Mike Elliott.
NVS: 91.90 (-0.71)
Nutritional High Building a Multi-State Edibles Manufacturing Platform
ACCESSWIRE - Wed Jun 10, 7:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 10, 2015 / Consistency is key. This is the philosophy under which Nutritional High is building its business from day 1. Headlines abound about marijuana edibles containing anywhere from 0 to 200% of the dosage stated on the package. Some purveyors of edibles, be it homemade brownies or products purchased at dispensaries, find dosing an issue. Testing in Colorado confirms that dosing is a significant challenge for marijuana edible companies as they try to ramp up production, and this is a challenge Nutritional High is taking up.
OGI.VN: 0.295 (+0.010)
Abattis Selects Ingredient Identity as Global Regulatory Management Partner
Marketwired - Mon May 11, 7:36AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce the engagement of Ingredient Identity, a preeminent regulatory management consulting firm to the Food, Dietary Supplement, Cosmetic and Homeopathic industries globally.
Abattis Appoints Hugh Oswald as Investor Relations
Marketwired - Fri May 01, 10:10AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015.
Abattis Bioceuticals Investor Update for Q2 2015
Marketwired - Tue Apr 28, 7:31AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (CSE: ATT)(OTCQX: ATTBF), a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announces a press release to update its current shareholders.
DigiPath Draws Press Coverage as Nevada Lab Prepares to Open
ACCESSWIRE - Mon Apr 27, 11:05AM CDT
WHITEFISH, MT / ACCESSWIRE / April 27, 2015 / Nevada legalized medical marijuana 15 years ago, but dispensaries are just now becoming a reality in the state. Given its large tourism industry and reciprocity laws, some analysts have projected that the state's cannabis industry could exceed $100 million in size over the coming years. The only thing holding the industry back are three bills that are currently pending in the state legislature which will finalize what the cannabis labs will be required to test for.
Abattis CEO Roadshow
Marketwired - Mon Apr 20, 1:20PM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds and patented equipment to medicinal markets in North America, would like to today announced that the Company's CEO, William Fleming ("Bill" wants to thank those that he has had the opportunity to meet during the most recent Company roadshow.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part I
Anthony Cataldo - at Seeking Alpha - Wed Apr 15, 9:38AM CDT
Affinor Growers and Abattis Bioceuticals Corp. Amicably Resolve Washington Litigation and Agree to Dismiss the Case With Prejudice
Marketwired - Fri Apr 10, 12:07PM CDT
Abattis Bioceuticals Corp. (OTCQX: ATTBF)(CSE: ATT) ("Abattis" wish to advise their shareholders that the litigation filed in King County, Washington State by Abattis and against Affinor, Affinor's Executive Director Nick Brusatore, and Affinor Growers LLC, has been amicably resolved and dismissed, leaving open the likelihood that the two companies will collaborate together in the future. Both parties unanimously agree that the lawsuits were both costly and time-consuming and a distraction for the growth of shareholder value for their respective companies.
Abattis Information to Be Available in S&P Capital IQ Market Access Program
Marketwired - Wed Mar 25, 3:01PM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds and patented equipment to medicinal markets in North America, would like to announced today that its company information will be made available via S&P Capital IQ's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of S&P Capital IQ's MarketScope Advisor. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. MarketScope Advisor is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://advisor.marketscope.com.
MHFI: 89.74 (+0.16)
S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Mar 25, 1:44PM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on Abattis Bioceuticals Corp.
MHFI: 89.74 (+0.16)
Cannabis Companies Hunt for Financing, Growth
at The Street - Fri Sep 25, 9:51AM CDT
Companies in the cannabis business have an appetite for capital to fuel what has emerged as one of the largest growth sectors, and more investors are taking the risk.
XXII: 1.08 (unch), FB: 93.24 (+0.77), PYPL: 32.06 (+0.39), ARNA: 2.19 (+0.14)
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 1.08 (unch), INSY: 25.65 (+0.64), ARNA: 2.19 (+0.14)
Abba Medix Builds a Diversified Business
ACCESSWIRE - Wed Jul 08, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 8, 2015 / Health Canada expects the country's medical marijuana market to dramatically expand over the coming years, growing from 22,000 patients in 2012 to more than 450,000 by 2024, representing a nearly 30% compounded annual growth rate. In dollar terms, the federal agency expects the market to reach approximately $1.2 billion in size, as the market moves from primarily home-growing to industrialized growers approved under the MMPR.
OGI.VN: 0.295 (+0.010), TWD.VN: 1.810 (-0.020), VPCO: 0.58 (+0.02)
Nutritional High Poised to Execute on U.S. Edibles Strategy, Hails Canadian Court Ruling
ACCESSWIRE - Tue Jul 07, 7:00AM CDT
WHITEFISH, MT / ACCESSWIRE / July 7, 2015 / Currently exclusively focused on manufacturing and distributing marijuana infused products (MIPs) like edibles and oils, as well as extracts produced with reliable semi automated processes, across U.S. states where such activity is already legal, Nutritional High International (OTCQB: SPLIF) (CSE: NHL) is coming out swinging with universally identifiable branding, featuring marijuana icon Jimi Hendrix on precisely formulated products that will survive longer on the shelf, taking the guesswork out of edibles for retailers and consumers alike. The company's strategy to leverage such iconic branding and roll out a number of marijuana and hemp oil-infused edibles in the U.S. and Canada bearing his likeness, was highlighted by David Posner, president and CEO of Nutritional High, in a recent interview with CannabisFN's Mike Elliott.
NVS: 91.90 (-0.71)
Nutritional High Building a Multi-State Edibles Manufacturing Platform
ACCESSWIRE - Wed Jun 10, 7:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 10, 2015 / Consistency is key. This is the philosophy under which Nutritional High is building its business from day 1. Headlines abound about marijuana edibles containing anywhere from 0 to 200% of the dosage stated on the package. Some purveyors of edibles, be it homemade brownies or products purchased at dispensaries, find dosing an issue. Testing in Colorado confirms that dosing is a significant challenge for marijuana edible companies as they try to ramp up production, and this is a challenge Nutritional High is taking up.
OGI.VN: 0.295 (+0.010)
Abattis Selects Ingredient Identity as Global Regulatory Management Partner
Marketwired - Mon May 11, 7:36AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, is pleased to announce the engagement of Ingredient Identity, a preeminent regulatory management consulting firm to the Food, Dietary Supplement, Cosmetic and Homeopathic industries globally. Abattis Appoints Hugh Oswald as Investor Relations
Marketwired - Fri May 01, 10:10AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announced that Hugh Oswald, will assume the role of Investor Relations of Abattis Bioceuticals Corp. effective April 29, 2015. Abattis Bioceuticals Investor Update for Q2 2015
Marketwired - Tue Apr 28, 7:31AM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(CSE: ATT)(OTCQX: ATTBF), a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, today announces a press release to update its current shareholders. DigiPath Draws Press Coverage as Nevada Lab Prepares to Open
ACCESSWIRE - Mon Apr 27, 11:05AM CDT
WHITEFISH, MT / ACCESSWIRE / April 27, 2015 / Nevada legalized medical marijuana 15 years ago, but dispensaries are just now becoming a reality in the state. Given its large tourism industry and reciprocity laws, some analysts have projected that the state's cannabis industry could exceed $100 million in size over the coming years. The only thing holding the industry back are three bills that are currently pending in the state legislature which will finalize what the cannabis labs will be required to test for.
Abattis CEO Roadshow
Marketwired - Mon Apr 20, 1:20PM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds and patented equipment to medicinal markets in North America, would like to today announced that the Company's CEO, William Fleming ("Bill" wants to thank those that he has had the opportunity to meet during the most recent Company roadshow. Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part I
Anthony Cataldo - at Seeking Alpha - Wed Apr 15, 9:38AM CDT
Affinor Growers and Abattis Bioceuticals Corp. Amicably Resolve Washington Litigation and Agree to Dismiss the Case With Prejudice
Marketwired - Fri Apr 10, 12:07PM CDT
Abattis Bioceuticals Corp. (OTCQX: ATTBF)(CSE: ATT) ("Abattis"
wish to advise their shareholders that the litigation filed in King County, Washington State by Abattis and against Affinor, Affinor's Executive Director Nick Brusatore, and Affinor Growers LLC, has been amicably resolved and dismissed, leaving open the likelihood that the two companies will collaborate together in the future. Both parties unanimously agree that the lawsuits were both costly and time-consuming and a distraction for the growth of shareholder value for their respective companies. Abattis Information to Be Available in S&P Capital IQ Market Access Program
Marketwired - Wed Mar 25, 3:01PM CDT
Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF)(CSE: ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds and patented equipment to medicinal markets in North America, would like to announced today that its company information will be made available via S&P Capital IQ's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of S&P Capital IQ's MarketScope Advisor. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. MarketScope Advisor is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://advisor.marketscope.com. MHFI: 89.74 (+0.16)
S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Mar 25, 1:44PM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on Abattis Bioceuticals Corp.
MHFI: 89.74 (+0.16)
